Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Apatinib, and Chemo Conversion Therapy for Stage IV Gastric Cancer
NCT04267549Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2019
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in gastric cancer (GC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04267549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267549.